Characteristics of the DISCOVeRY-BMT cohort
| Recipient characteristics . | First cohort, N = 2111 . | Second cohort, N = 777 . | P . |
|---|---|---|---|
| n (%) . | |||
| Age, y | |||
| ≥40 | 1314 (62) | 525 (68) | .01 |
| <40 | 797 (38) | 252 (32) | |
| Donor age range (mean) | 18-61 (34) | 18-60 (32) | <.01 |
| Sex | |||
| Male | 1191 (56) | 429 (55) | NS |
| Female | 920 (44) | 348 (45) | |
| Donor sex | |||
| Male | 1437 (68) | 563 (72) | .03 |
| Female | 674 (32) | 214 (28) | |
| Disease | |||
| AML | 1283 (61) | 488 (63) | <.01 |
| ALL | 483 (23) | 94 (12) | |
| MDS | 345 (16) | 195 (25) | |
| AML disease status | |||
| Early | 588 (46) | 271 (56) | <.01 |
| Intermediate | 321 (25) | 101 (21) | |
| Advanced | 374 (29) | 116 (24) | |
| ALL disease status | |||
| Early | 188 (39) | 47 (50) | .023 |
| Intermediate | 207 (43) | 26 (28) | |
| Advanced | 88 (18) | 21 (22) | |
| MDS disease status | |||
| Early | 230 (67) | 68 (35) | <.01 |
| Advanced | 115 (33) | 128 (65) | |
| Karnofsky performance score/Lansky performance status | |||
| 90-100 | 1283 (61) | 490 (63) | NS |
| <90 | 619 (29) | 248 (32) | |
| Year of HCT | |||
| 2000-2002 | 352 (17) | 30 (4) | <.01 |
| 2003-2005 | 758 (36) | 67 (9) | |
| 2006-2008 | 1001 (47) | 100 (13) | |
| 2009-2011 | 0 (0) | 580 (75) | |
| BMI | |||
| Underweight | 41 (2) | 20 (3) | .02 |
| Normal | 780 (37) | 241 (31) | |
| Overweight | 659 (31) | 266 (34) | |
| Obese | 631 (30) | 250 (32) | |
| Graft source | |||
| Bone marrow | 745 (35) | 210 (27) | <.01 |
| Peripheral blood | 1366 (65) | 567 (73) | |
| Conditioning regimen | |||
| Myeloablative | 1540 (73) | 552 (71) | NS |
| Reduced intensity | 571 (27) | 225 (29) | |
| Recipient characteristics . | First cohort, N = 2111 . | Second cohort, N = 777 . | P . |
|---|---|---|---|
| n (%) . | |||
| Age, y | |||
| ≥40 | 1314 (62) | 525 (68) | .01 |
| <40 | 797 (38) | 252 (32) | |
| Donor age range (mean) | 18-61 (34) | 18-60 (32) | <.01 |
| Sex | |||
| Male | 1191 (56) | 429 (55) | NS |
| Female | 920 (44) | 348 (45) | |
| Donor sex | |||
| Male | 1437 (68) | 563 (72) | .03 |
| Female | 674 (32) | 214 (28) | |
| Disease | |||
| AML | 1283 (61) | 488 (63) | <.01 |
| ALL | 483 (23) | 94 (12) | |
| MDS | 345 (16) | 195 (25) | |
| AML disease status | |||
| Early | 588 (46) | 271 (56) | <.01 |
| Intermediate | 321 (25) | 101 (21) | |
| Advanced | 374 (29) | 116 (24) | |
| ALL disease status | |||
| Early | 188 (39) | 47 (50) | .023 |
| Intermediate | 207 (43) | 26 (28) | |
| Advanced | 88 (18) | 21 (22) | |
| MDS disease status | |||
| Early | 230 (67) | 68 (35) | <.01 |
| Advanced | 115 (33) | 128 (65) | |
| Karnofsky performance score/Lansky performance status | |||
| 90-100 | 1283 (61) | 490 (63) | NS |
| <90 | 619 (29) | 248 (32) | |
| Year of HCT | |||
| 2000-2002 | 352 (17) | 30 (4) | <.01 |
| 2003-2005 | 758 (36) | 67 (9) | |
| 2006-2008 | 1001 (47) | 100 (13) | |
| 2009-2011 | 0 (0) | 580 (75) | |
| BMI | |||
| Underweight | 41 (2) | 20 (3) | .02 |
| Normal | 780 (37) | 241 (31) | |
| Overweight | 659 (31) | 266 (34) | |
| Obese | 631 (30) | 250 (32) | |
| Graft source | |||
| Bone marrow | 745 (35) | 210 (27) | <.01 |
| Peripheral blood | 1366 (65) | 567 (73) | |
| Conditioning regimen | |||
| Myeloablative | 1540 (73) | 552 (71) | NS |
| Reduced intensity | 571 (27) | 225 (29) | |
BMI, body mass index; HCT, hematopoietic cell transplantation; NS, not significant.